Our board

Marc Gordon, Chairman

Marc joined the Myeloma UK Board of Directors in 2012 as Treasurer and took over the Chairman role in January 2019. He is the Co-founder of Nimrod Capital, an independent investment management and advisory business.

Marc read law at Cambridge University and following his graduation, became an Investment Manager at NM Rothschild. Previous roles have also included Co-founder and Managing Director of Close Fund Management and Director at John Govett & Co Ltd.

Marc said, “Myeloma UK has already done fantastic things with limited resources and I believe it can do so much more for patients over the coming years.”

Sir Frank Chapman, Vice Chairman

Sir Frank Chapman, who was diagnosed with myeloma in 2010, joined the Myeloma UK Board of Directors in 2016.

Sir Frank worked in the international oil and gas industry for 40 years. He began his career with BP, followed by an 18-year career with Shell before joining British Gas as Managing Director Exploration and Production in 1996. In 2000, Sir Frank was appointed Chief Executive of BG Group plc, a role from which he retired in 2013.

He has received a number of awards throughout his career and was knighted in 2011 for his services to the oil and gas industries. Alongside his role with Myeloma UK, Sir Frank is also a Non-Executive Director at Rolls-Royce where he chairs the Safety and Ethics Committee.

Sir Frank said, “I was delighted to be invited to join the Board at Myeloma UK. The organisation’s work entails a fascinating combination of patient support, education, cutting-edge
research and promoting innovative collaboration between all the key stakeholders involved in getting new effective treatments to patients. I very much look forward to playing a
role in delivering our diverse and potentially game-changing work.”

David Allmond, Director

David joined the Myeloma UK Board of Directors in 2013.

He is currently President, EMEA for Aegerion Pharmaceuticals which focuses exclusively on bringing innovative therapies to people with very rare, debilitating diseases.

David has over 20 years of experience working in the European pharmaceutical industry. He has worked for a range of pharmaceutical companies including Celgene where he held the role of General Manager at Celgene UK Ltd, and latterly Corporate Vice President of Global Marketing in the United States.

Whilst at Celgene UK Ltd, he founded the Orphan Disease Industry Group and worked collaboratively with stakeholders, including Myeloma UK, to improve access to medicines for people with rare cancers in the UK.

David said, “I admire the fact that Myeloma UK has had, and continues to have, the foresight to collaborate. It’s a real trademark. By collaborating with clinicians, industry, the NHS, Government and patient groups, Myeloma UK puts the needs of the patient at the forefront of everything the organisation does and that really sets it apart.”

Lee Appleton, Director

Lee Appleton joined the Myeloma UK Board of Directors in 2013.

Lee spent nine years working in New York organising and managing events and conventions for a large resort hotel. Since returning to the UK in 2000 Lee has focused on fundraising and supporting various charities.

Lee’s mother was diagnosed with myeloma in 2011. She has since been actively involved in fundraising for Myeloma UK.

Lee said, “Being part of the dynamic Myeloma UK team is a tremendous privilege. For me it’s a true labour of love to dedicate my time and efforts to raising funds for the life-changing work Myeloma UK does.”

Susan Blair RGN, Director

Sue Blair has been a member of the Myeloma UK Board of Directors since 2010.

In 2001 Sue became a Myeloma Clinical Nurse Specialist at The Christie in Manchester where she currently manages the haematology day unit. She qualified as a nurse in 1984 and her early career focused on haematology and palliative care.

Sue previously held the role of Nurse Transplant Coordinator at University College London Hospitals, was a community based Palliative Care Nurse at St Christopher’s Hospice in London and spent a year as a Macmillan Nurse.

Sue said, “I’ve been involved with Myeloma UK since 2001. I’ve worked with the organisation hosting seminars for the Patient and Family Myeloma Infodays and on the nurse education
programmes; what is clear to me is the importance education has to play in managing patient outcomes.”

Dr Karthik Ramasamy, Director

Dr Karthik Ramasamy joined the Myeloma UK Board of Directors in 2019.

Dr Ramasamy is a consultant haematologist at Oxford University Hospitals NHS Trust and the Director of the Oxford Myeloma Translational Research Centre. He is also Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Strategic Clinical Network. He has been a Chief Investigator of myeloma studies in renal impairment and bone disease and Principal Investigator on several myeloma trials.

Geraldine Haley, Director

Geraldine Haley joined the Myeloma UK Board of Directors in 2019.

Geraldine Haley has spent 25 years with Standard Chartered Bank, where she gained generalist and specialist Human Resources experience, including time as Global Head of HR for Corporate and Institutional Banking and culminating in her role as Global Head of Executive Talent. Geraldine set-up a consulting practice in 2016 where she focuses on coaching Senior Executives, accelerating team performance and bespoke leadership development programmes.